20-Day MA Supports Holding on SPX, QQQ, IWM The S&P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM) each continue to hold above short-term support at their respective 20-day MAs (currently 5966 on SPX, $526.50 on QQQ, and $208.75 on IWM) -- and have not closed below their 20-day MAs for two months. As long as 20-day MA supports hold, our near-term bullish outlook that we have had since our 4/22/25 Compass remains intact. We will need to see breakdowns below 20-day MA supports in order to ex...
Dave & Buster’s Announces Promotion of Les Lehner to Chief Development Officer DALLAS, June 13, 2025 (GLOBE NEWSWIRE) -- Dave & Buster's Entertainment, Inc., (NASDAQ: PLAY), ("Dave & Buster's" or "the Company") today announced that it has promoted Les Lehner to the position of Chief Development Officer. Mr. Lehner most recently served as Chief Procurement Officer and Head of Main Event Development. In connection with this promotion, the Company announced that John Mulleady, current Chief Development Officer, will retire effective as of the close of business on October 23, 2025. Effective...
Cabaletta Bio Announces Pricing of Public Offering of Securities PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten public offering consisting of (i) 39,200,000 shares of its common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock (or pre-funded warrants in li...
Cabaletta Bio Announces Proposed Public Offering of Securities PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock, to certa...
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress – 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding patients – – All SLE patients without nephropathy achieved definition of remission in SLE (DORIS) as of the latest follow-up, and all 7 SLE and LN patients experienced SLEDAI-2K reductions, while off all imm...
Dave & Buster’s Reports First Quarter 2025 Financial Results DALLAS, June 10, 2025 (GLOBE NEWSWIRE) -- Dave & Buster's Entertainment, Inc., (NASDAQ: PLAY), (“Dave & Buster's” or “the Company”), an owner and operator of entertainment and dining venues, today announced financial results for its first quarter of fiscal 2025 ended May 6, 2025. First Quarter 2025 Financial Summary First quarter revenue of $567.7 million decreased 3.5% from the first quarter of fiscal 2024.Comparable store sales decreased 8.3% compared to the same calendar period in fiscal 2024.Net income totaled $21.7 millio...
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 11:05 a.m. ET in New York, NY. A live webcast of the presentation will be available on the News and Events sect...
Dave & Buster’s Entertainment, Inc. to Report First Quarter 2025 Financial Results on June 10, 2025 DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Dave & Buster's Entertainment, Inc., (NASDAQ:PLAY), ("Dave & Buster's" or "the Company"), an owner and operator of entertainment and dining venues, today announced that it will report financial results for its first quarter ended May 6, 2025 after the market closes on Tuesday, June 10, 2025. Management will host a conference call to discuss these results on Tuesday, June 10, 2025, at 4:00 p.m. Central Time (5:00 p.m. Eastern Time). A live and archiv...
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts – Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis™ trial – – RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. patients with no approved treatments other than monthly IVIg – – Multiple Phase 1/2 disease cohorts fully enrolled across the RESET™ clinical development program; 44 patients enrolled and 23 patients dosed as of...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.